Repro Med Systems Inc
NASDAQ:KRMD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.04
3.81
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Repro Med Systems Inc
Repro Med Systems Inc
Cash & Cash Equivalents
Repro Med Systems Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Repro Med Systems Inc
NASDAQ:KRMD
|
Cash & Cash Equivalents
$11.5m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
25%
|
CAGR 10-Years
20%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
26%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
55%
|
CAGR 10-Years
26%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$3.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$2.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
17%
|
|
Repro Med Systems Inc
Glance View
Repro-Med Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. The company is headquartered in Chester New York, New York and currently employs 77 full-time employees. The company is focused on the developing, manufacturing, and commercializing of specialty infusion solutions. The firm's products include the FREEDOM Infusion Systems, which consist of the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgHFlo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The FREEDOM System operates at a lower pressure and maintains a balance between what a patient’s subcutaneous tissues can absorb and what the system delivers. The firm performs product assembly, calibration, pre- and post-assembly quality control inspection and testing, and final packaging for all its products at its Chester, New York facility.
See Also
What is Repro Med Systems Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
11.5m
USD
Based on the financial report for Dec 31, 2023, Repro Med Systems Inc's Cash & Cash Equivalents amounts to 11.5m USD.
What is Repro Med Systems Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
20%
Over the last year, the Cash & Cash Equivalents growth was -34%. The average annual Cash & Cash Equivalents growth rates for Repro Med Systems Inc have been -25% over the past three years , 25% over the past five years , and 20% over the past ten years .
You don't have any saved screeners yet
